Closeout of four phase II Vanguard trials and patient rollover into a large international phase III HIV clinical endpoint trial

Controlled Clinical Trials

Volumn 22, Issue 1, 2001, Pages 42-48

  Tavel, Jorge A ^a   Fosdick, Lisa ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Continued follow up; Feasibility; HIV clinical endpoint trial; Patient rollover; Trial closeout

Indexed keywords

ANTIRETROVIRUS AGENT; INTERLEUKIN 2;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMED CONSENT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS, PHASE II; DATA COLLECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INTERLEUKIN-2; MALE; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT SELECTION; PILOT PROJECTS; SURVIVAL RATE;

EID: 0035128924     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(00)00114-8     Document Type: Article

References (13)

1. Interleukin 2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism
2. 3: Results of a randomized, controlled clinical trial
3. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type-1 infected persons
4. A randomised controlled, multicentre outpatient trial of intravenous or subcutaneous interleukin-2 in HIV-infected patients
5. A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection
6. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: A randomized controlled trial
7. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy
8. AIDS therapy: Ambitious clinical trial stirs debate
9. 3
10. A randomized, controlled 24 week study of intermittent subcutaneous interleukin-2 (IL-2) in HIV-1 infected patients in Thailand
11. IL-2 therapy produces no change in HIV-RNA after one year
12. CARET, the B-carotene and retinol efficacy trial to prevent lung cancer in asbestos-exposed workers and in smokers
13. Thirty years of Medical Research Council randomized trials in solid tumors